Search Results Search Sort by RelevanceMost Recent Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838. Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Case and Commentary Sep 2019 What Are Criteria for Considering Technologies’ Uses and Influences in LMICs’ Health Care Infrastructures? Rolvix Patterson and Richard Rohrer, MD Low-resource areas are heterogeneous and changing, so establishing an evidence base for decision making about technology use is an important priority. AMA J Ethics. 2019;21(9):E735-741. doi: 10.1001/amajethics.2019.735. Case and Commentary Feb 2019 Should Watson Be Consulted for a Second Opinion? David D. Luxton, PhD, MS Guidance for organizations using AI tools to diagnose and to develop treatment recommendations can also help clinicians consider risks and benefits. AMA J Ethics. 2019;21(2):E131-137. doi: 10.1001/amajethics.2019.131. Case and Commentary Jan 2020 How Should Public Health Officials Respond When Important Local Rituals Increase Risk of Contagion? Esther Mokuwa, MSc and Paul Richards, PhD, MA During one 2014 Ebola epidemic, arrival of “safe burial” teams was often delayed. Some buried their loved ones themselves, which undermined containment efforts. AMA J Ethics. 2020;22(1):E5-9. doi: 10.1001/amajethics.2020.5. Case and Commentary Jan 2020 How Should Clinicians Integrate Mental Health Into Epidemic Responses? Shantanu Srivatsa and Kearsley A. Stewart, PhD Culturally appropriate responsiveness to mental illnesses is critical to mitigating local persons’ distrust of international clinicians. AMA J Ethics. 2020;22(1):E10-15. doi: 10.1001/amajethics.2020.10. Case and Commentary Feb 2020 How Should Physicians in Low- and Middle-Income Countries Regard Electronic Nicotine Delivery Systems to Facilitate Smoking Cessation? Thomas E. Novotny, MD, MPH, DSc (Hon) and May C. I. van Schalkwyk, MBBS, MPH Vaping has been thought to be a safe, effective smoking cessation aid, but little evidence supports its value in mitigating tobacco use. AMA J Ethics. 2020;22(2):E82-92. doi: 10.1001/amajethics.2020.82. Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Case and Commentary Oct 2019 How Should a Physician Respond to a Patient’s Pain When New Opioid Prescribing Laws Limit Shared Decision Making? Alexander J. Hjelmaas, MD and Christian J. Vercler, MD, MA Regulations’ negative influence on patient-physician relationships can be mitigated by innovation in decision science. AMA J Ethics. 2019;21(10):E838-843. doi: 10.1001/amajethics.2019.838.
Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.
Case and Commentary Sep 2019 What Are Criteria for Considering Technologies’ Uses and Influences in LMICs’ Health Care Infrastructures? Rolvix Patterson and Richard Rohrer, MD Low-resource areas are heterogeneous and changing, so establishing an evidence base for decision making about technology use is an important priority. AMA J Ethics. 2019;21(9):E735-741. doi: 10.1001/amajethics.2019.735.
Case and Commentary Feb 2019 Should Watson Be Consulted for a Second Opinion? David D. Luxton, PhD, MS Guidance for organizations using AI tools to diagnose and to develop treatment recommendations can also help clinicians consider risks and benefits. AMA J Ethics. 2019;21(2):E131-137. doi: 10.1001/amajethics.2019.131.
Case and Commentary Jan 2020 How Should Public Health Officials Respond When Important Local Rituals Increase Risk of Contagion? Esther Mokuwa, MSc and Paul Richards, PhD, MA During one 2014 Ebola epidemic, arrival of “safe burial” teams was often delayed. Some buried their loved ones themselves, which undermined containment efforts. AMA J Ethics. 2020;22(1):E5-9. doi: 10.1001/amajethics.2020.5.
Case and Commentary Jan 2020 How Should Clinicians Integrate Mental Health Into Epidemic Responses? Shantanu Srivatsa and Kearsley A. Stewart, PhD Culturally appropriate responsiveness to mental illnesses is critical to mitigating local persons’ distrust of international clinicians. AMA J Ethics. 2020;22(1):E10-15. doi: 10.1001/amajethics.2020.10.
Case and Commentary Feb 2020 How Should Physicians in Low- and Middle-Income Countries Regard Electronic Nicotine Delivery Systems to Facilitate Smoking Cessation? Thomas E. Novotny, MD, MPH, DSc (Hon) and May C. I. van Schalkwyk, MBBS, MPH Vaping has been thought to be a safe, effective smoking cessation aid, but little evidence supports its value in mitigating tobacco use. AMA J Ethics. 2020;22(2):E82-92. doi: 10.1001/amajethics.2020.82.